

A3
CONT.

9. (Amended) Process for identifying substances which affect the promoter activity, silencer activity or enhancer activity of the human catalytic telomerase subunit, comprising the following steps:

- A. adding a candidate substance to a host cell which harbours DNA sequences according to [one of] Claim[s] 1 [to 3] which sequences are functionally linked to a reporter gene, and
- B. measuring the effect of the substance on expression of the reporter gene.

10. (Amended) Process for identifying factors which bind specifically to the DNA according to [one of] Claim[s] 1 [to 3], or to fragments thereof, characterized in that an expression cDNA library is screened using a DNA sequence according to [one of] Claim[s] 1 [to 3], or sub-fragments of widely differing length, as the probe.

11. (Amended) Transgenic animals which harbour recombinant constructs or vectors according to Claim[s] 4 [to 6].

12. (Amended) Process for detecting telomerase-associated conditions in a patient, comprising the following steps:

- A. incubating a recombinant construct or vector according to Claim[s] 4 [to 6], which additionally contains a reporter gene, with body fluids or cell samples,
- B. detecting the activity of the reporter gene in order to obtain a diagnostic value, and
- C. comparing the diagnostic value with standard values for the reporter gene activity in healthy individuals and all other body fluids of the